These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 9713875)

  • 61. Urinary inhibitory activity of calcium oxalate monohydrate crystal growth in stone-formers & non stone-formers.
    Sidhu H; Vaidyanathan S; Wangoo D; Rattan V; Thind SK; Nath R; Malakondaiah GC; Tandon SP
    Indian J Med Res; 1987 Oct; 86():500-5. PubMed ID: 3443483
    [No Abstract]   [Full Text] [Related]  

  • 62. Polyanionic inhibitors of calcium oxalate crystal agglomeration in urine.
    Scurr DS; Latif AB; Sergeant V; Robertson WG
    Proc Eur Dial Transplant Assoc; 1983; 20():440-4. PubMed ID: 6197713
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Binding of glycosaminoglycans to sodium urate and uric acid crystals.
    Fellström B; Lindsjö M; Danielson BG; Ljunghall S; Wikström B
    Clin Sci (Lond); 1986 Jul; 71(1):61-4. PubMed ID: 2423287
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Surface interaction between glycosaminoglycans and calcium oxalate.
    Angell AH; Resnick MI
    J Urol; 1989 May; 141(5):1255-8. PubMed ID: 2709520
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The effect of two new semi-synthetic glycosaminoglycans (G871, G872) on the zeta potential of calcium oxalate crystals and on growth and agglomeration.
    Cao LC; Boevé ER; Schröder FH; Robertson WG; Ketelaars GA; de Bruijn WC
    J Urol; 1992 Jun; 147(6):1643-6. PubMed ID: 1593714
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Evaluation of the relative inhibitory potential of fractionated urinary macromolecules.
    Azoury R; Goldwasser B; Wax Y; Perlberg S; Garti N; Sarig S
    Urol Res; 1985; 13(4):199-205. PubMed ID: 4049608
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Studies on calcium oxalate crystallization propensity in human urine. 2. Clinical studies using an aggregometer].
    Yoshida T
    Nihon Hinyokika Gakkai Zasshi; 1987 Oct; 78(10):1701-6. PubMed ID: 3444161
    [No Abstract]   [Full Text] [Related]  

  • 68. Crystallization in gel matrices: a new experimental model of calcium stone formation.
    Achilles W
    Contrib Nephrol; 1987; 58():59-64. PubMed ID: 3691148
    [No Abstract]   [Full Text] [Related]  

  • 69. [Effects of malate, succinate and bicarbonate salts in preventing experimental oxalate urolithiasis in rats].
    Yamaguchi K; Ogawa Y; Morozumi M; Tanaka T; Kitagawa R
    Nihon Hinyokika Gakkai Zasshi; 1987 Feb; 78(2):311-8. PubMed ID: 3613335
    [No Abstract]   [Full Text] [Related]  

  • 70. Release of plasminogen activator by pentosan polysulphate.
    Klöcking HP; Markwardt F
    Thromb Res; 1986 Mar; 41(5):739-44. PubMed ID: 2421436
    [No Abstract]   [Full Text] [Related]  

  • 71. Role of scanning electron microscopy in identifying drugs used in medical practice.
    Fazil Marickar YM; Sylaja N; Koshy P
    Urol Res; 2009 Oct; 37(5):299-303. PubMed ID: 19711065
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Inhibitory effects of urinary calcium-binding substances on calcium oxalate crystallization.
    Resnick MI; Sorrell ME; Bailey JA; Boyce WH
    J Urol; 1982 Mar; 127(3):568-71. PubMed ID: 7062442
    [No Abstract]   [Full Text] [Related]  

  • 73. Inhibition of sodium urate crystal adherence to bladder surface by polysaccharide.
    Parsons CL; Danielson B; Feldstrom B
    J Urol; 1985 Sep; 134(3):614-6. PubMed ID: 2411955
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pharmacokinetics of intravenous pentosan polysulphate (HOE/BAY 946) in HIV-positive patients.
    Peters M; Witvrouw M; De Clercq E; Ruf B
    AIDS; 1991 Dec; 5(12):1534-5. PubMed ID: 1726041
    [No Abstract]   [Full Text] [Related]  

  • 75. Reduction of urinary basic fibroblast growth factor using pentosan polysulphate sodium.
    Barrington JW; Fulford S; Fraylin L; Fish R; Shelley M; Stephenson TP
    Br J Urol; 1996 Jul; 78(1):54-6. PubMed ID: 8795400
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Effect of the heparinoid pentosan polysulphate (SP 54) on the functional properties of cultured bovine aortic endothelial cells.
    Delvos U; Paul JE; Müller-Berghaus G
    Blut; 1985 Sep; 51(3):127-36. PubMed ID: 2411313
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effect of pentosan, a novel cancer chemotherapeutic agent, on prostate cancer cell growth and motility.
    Pienta KJ; Murphy BC; Isaacs WB; Isaacs JT; Coffey DS
    Prostate; 1992; 20(3):233-41. PubMed ID: 1374181
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Role of glycosaminoglycans relating to formation of urolithiasis].
    Nishio S
    Nihon Hinyokika Gakkai Zasshi; 1995 Nov; 86(11):1597-609. PubMed ID: 8551701
    [No Abstract]   [Full Text] [Related]  

  • 79. Prevention of acrolein-induced bladder injury by pentosanpolysulfate.
    Kalota SJ; Stein PC; Parsons CL
    J Urol; 1992 Jul; 148(1):163-6. PubMed ID: 1377288
    [TBL] [Abstract][Full Text] [Related]  

  • 80. From computational prediction to experimental validation: Hesperidin's anti-Urolithiatic activity in sodium oxalate-induced urolithiasis models in fruit flies and mice.
    Kale MD; Kadam SP; Shravage BV; Nikam VS
    Toxicol Appl Pharmacol; 2024 Nov; 492():117104. PubMed ID: 39276927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.